Cyclical combination chemotherapy for advanced breast carcinoma

Area of Science:

• Oncology
• Medical Oncology
• Pharmacology

Background:

• Advanced metastatic breast cancer presents a significant treatment challenge.
• Patients with advanced disease often have limited therapeutic options, especially after hormonal therapy failure.

Purpose of the Study:

• To evaluate the efficacy and toxicity of a specific combination chemotherapy regimen in patients with advanced metastatic breast cancer.
• To assess response rates, duration of response, and survival outcomes.

Main Methods:

• A cohort of 25 patients with advanced metastatic breast cancer received a combination of methotrexate, 5-fluorouracil, cyclophosphamide, and prednisone.
• Patients had no prior chemotherapy or extensive radiotherapy and were largely unresponsive to hormonal therapy.
• Treatment involved intravenous and oral administration over a 28-day cycle.

Main Results:

• A 68% overall response rate was observed in 17 out of 25 patients, including seven complete remissions.
• The median duration of response was nine months.
• Haematological toxicity was the primary concern, particularly in patients with liver dysfunction or bone marrow involvement.

Conclusions:

• The studied combination chemotherapy regimen demonstrates significant efficacy in advanced metastatic breast cancer, leading to improved survival.
• The treatment is associated with manageable toxicity, primarily hematological.
• Response to this regimen correlates with a substantially longer median survival compared to non-responders.